Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of treatment. “It’s quite remarkable,” said Paul Mulholland, consultant oncologist at University College Hospital London, and chief investigator of the Phase I study. The trial will recruit patients with recurrent disease who have undergone surgery to remove as much of the tumor as possible; the radiopharmaceutical is delivered weekly via a small implant under the scalp.

That small success, which made UK headlines, hints at remarkable progress and dealmaking action across the radiopharmaceuticals pipeline.